CodeBlue urges Malaysian MPs to vote for tobacco control bill

Jul.18.2022
CodeBlue urges Malaysian MPs to vote for tobacco control bill
Malaysian health NGO, CodeBlue, urges lawmakers to support the Tobacco and Smoking Control Bill to ban cigarettes for those born after 2005.

CodeBlue, a non-profit health organization in Malaysia, is urging lawmakers to vote in support of the "Tobacco and Smoking Control Bill," which would prohibit individuals born after 2005 from purchasing and using cigarettes. Here is the full statement.


The crucial "Tobacco and Smoking Control Act" will be submitted to Parliament this week, which will have an impact on the health and social welfare of our future generations. It is crucial that all members of Parliament fully understand these issues and support this important legislation.


It is important to note that this bill does not restrict smoking among adults, but rather aims to prohibit the sale and use of cigarettes and e-cigarette products to all children born after 2005 (those who will turn 18 in 2023).


Smoking is a rapidly growing epidemic among our children. The 2019 national health and disease rate survey provides us with national data on adolescent smoking behavior. The data is alarming for children aged 15 to 19, as it shows a significant increase in smoking rates.


At present, there are 303,800 smokers, accounting for 11.6% of the population.


A total of 196,000 individuals, which is equivalent to 7.5% of the population, are currently using e-cigarettes.


15.6% of teenagers aged 15 to 19 are currently using tobacco products.


It is anticipated that since the investigation, there has been a significant increase in the number of adolescents who have started using electronic cigarettes in recent years. As pediatricians, we are aware that many young children are drawn to using electronic cigarette products due to their appealing flavors and stylish devices, as well as the desire to appear "cool".


Teenagers smoking electronic cigarettes and becoming addicted can be seen throughout the country. It is widely recognized that most smokers develop their habit in their teens, and smoking e-cigarettes only makes it easier to develop addiction.


Worrying statistics have emerged from the Malaysian National Tobacco and E-cigarette Survey among Youth (TECMA), which shows that 9.1% of Malaysian youths aged 10 to 19 currently use e-cigarettes, with at least 600,000 children included in this group. Among these children, half started using e-cigarettes before the age of 14.


Smoking addiction is extremely difficult to overcome. Some users will gradually turn to more addictive and harmful drugs.


We urge our congressional representatives to consider the health and well-being of all of our children. Please vote in favor of the Tobacco Control Act. The impact of eliminating a major source of social ills and reducing the long-term health problems and death tolls cannot be overstated.


Voting in favor of this bill is a vote in support of investing in the current and future health and well-being of our children.


Voting in favor of the bill represents a vote of hope for all families whose children are no longer addicted to drugs or e-cigarettes.


Voting in favor of the bill is a vote in support of our healthcare system to alleviate the burden of major illnesses.


Dr. Amar-Singh HSS is a pediatric consultant.


Dr. Selva Kumar is a pediatric consultant and the president of the Malaysian Pediatric Association (MPA).


Dr. Musa Mohd Nordin, pediatric consultant.


Dr. Zulkifli Ismail, Pediatric Consultant.


Dr. Thiyagar Nadarajaw is a pediatric consultant and vice president of the Malaysian Adolescent Health Association (MAAH).


Please provide context and the original text to be translated.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
Former BAT global content lead Andy Parton has left the company and launched Destreza, a London-based AI-native marketing consultancy. Parton previously worked across BAT's New Category brands Vuse, Velo and glo and had also served as Global Brand Lead for Vuse Go. Destreza says it will advise consumer businesses on AI in brand strategy, operating models, capability and agency configuration, using specialist AI agents to support research, strategy and creative development. BAT reported £3.621 billion in New Category revenue in 2025.
Sep.22
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
IVG Parent Secures HMRC Excise Warehouse and Duty Stamp Approvals Ahead of UK Vape Tax
IVG Parent Secures HMRC Excise Warehouse and Duty Stamp Approvals Ahead of UK Vape Tax
Acme Vape Ltd, the company behind UK vaping brand IVG, has received HM Revenue & Customs approval to operate an excise warehouse for vaping products and participate in the Vaping Duty Stamps Scheme. The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Acme Vape Ltd says its approved warehouse in Preston will become operational under the new regime on the same date.
Regulations
Sep.18 by 2Firsts Perspectives
Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
China’s State Council has appointed Zhang Xiaotang as deputy director of the State Tobacco Monopoly Administration, with the regulator’s official website now listing him as a Party leadership group member and deputy director. Zhang previously led Hebei China Tobacco and earlier headed the STMA’s finance and audit department. His appointment follows the elevation earlier this year of former tax official Yao Laiying to head the STMA, adding another senior official with a strong fiscal or financial-management background to China Tobacco’s top leadership in 2026.
News
Sep.20
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30